Tocilizumab and Cytokine Release Syndrome (CRS) In Covid-19 Pneumonia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

24 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-04-28

Study Completion Date

2020-06-22

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tocilizumab (TCZ), interleukin-6 (IL-6), newly appeared as treatment of cytokine release syndrome (CRS) in patients with severe covid-19 associated pneumonia. In the present study, we aimed to discuss the treatment response of TCZ therapy in COVID-19 infected patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Xylitol Based Nasal Spray for COVID-19 Treatment

NCT05618483

Respiratory Viral Infection

UNKNOWN NA

Hypertonic Saline Enhances The Field of View of Clinicians and Ease of Procedures

NCT04214938

Nasopharyngeal Diseases

COMPLETED PHASE4

Efficacy and Safety of Xylitol Nasal Irrigation After Functional Endoscopic Sinus Surgery

NCT06108921

Chronic Rhinosinusitis Postoperative Care

COMPLETED NA

Assessing the Effects of a Nasal Corticosteroid on PMI-150 (Intranasal Ketamine)

NCT00662883

Healthy

COMPLETED PHASE1

SA55 Novel Coronavirus Broad-spectrum Neutralizing Antibody Nasal Spray in Health People

NCT06048393

COVID-19

UNKNOWN PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This observational study was designed just to visualize the efficacy and safety of Tocilizumab, an antibody anti-IL-6 receptor in patients with moderate to severe COVID-19 with increased inflammatory markers.Patients will be followed until Day 29 after randomization.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cytokine Release Syndrome Covid-19 Pneumonia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Case Group

All the patients suffering from severe covid pneumonia and laboratory parameter suggestive of cytokine release syndrome.

Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)

Intervention Type DRUG

Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tocilizumab 200 Mg/10 mL (20 Mg/mL) INTRAVEN VIAL (ML)

Tocilizumab was given according to weight in patients with cytokinme releasew syndrome (CRS).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Actemra

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age ≥ 18 years old; Clinical diagnosis of SARS-CoV-2 virus by PCR, or by other approved diagnostic methodology, or, with presumptive diagnosis of COVID-19 (other respiratory causes ruled out and COVID-19 test pending); Hospitalized with COVID-19-induced pneumonia; Elevated CRP, D-Dimers or ferritin levels; Bodyweight ≥ 40kg.

Exclusion Criteria

* Eligible patients must not have a history of hypersensitivity to any drugs or metabolites of similar chemical classes as canakinumab; Use of tocilizumab within 3 weeks prior; Suspected or known active bacterial, fungal, or parasitic infection (besides COVID-19); Patients with significant neutropenia (ANC \<1000/mm3); Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) prior to tocilizumab dose.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No